Pfizer Inc. (NYSE:PFE) Stock Position Lifted by Modern Wealth Management LLC

Modern Wealth Management LLC increased its position in Pfizer Inc. (NYSE:PFE - Free Report) by 48.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 42,336 shares of the biopharmaceutical company's stock after buying an additional 13,865 shares during the period. Modern Wealth Management LLC's holdings in Pfizer were worth $1,095,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of PFE. Segall Bryant & Hamill LLC grew its holdings in Pfizer by 4.3% in the 4th quarter. Segall Bryant & Hamill LLC now owns 76,539 shares of the biopharmaceutical company's stock valued at $2,031,000 after buying an additional 3,177 shares during the period. CoreFirst Bank & Trust purchased a new stake in Pfizer in the fourth quarter valued at approximately $226,000. Barnett & Company Inc. increased its position in Pfizer by 4.3% during the fourth quarter. Barnett & Company Inc. now owns 222,898 shares of the biopharmaceutical company's stock worth $5,913,000 after purchasing an additional 9,273 shares during the last quarter. Prudential Financial Inc. boosted its holdings in shares of Pfizer by 67.5% in the 4th quarter. Prudential Financial Inc. now owns 6,927,537 shares of the biopharmaceutical company's stock valued at $183,788,000 after purchasing an additional 2,792,786 shares during the last quarter. Finally, Lynx Investment Advisory grew its stake in shares of Pfizer by 14.2% during the 4th quarter. Lynx Investment Advisory now owns 31,161 shares of the biopharmaceutical company's stock valued at $827,000 after buying an additional 3,866 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.

Remove Ads

Pfizer Stock Performance

Shares of PFE traded up $0.19 during mid-day trading on Friday, hitting $25.20. The stock had a trading volume of 32,322,049 shares, compared to its average volume of 39,037,478. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a market cap of $142.93 billion, a PE ratio of 17.87, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company's fifty day simple moving average is $26.06 and its two-hundred day simple moving average is $26.92.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the previous year, the firm earned $0.10 earnings per share. The firm's revenue for the quarter was up 24.7% compared to the same quarter last year. On average, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on PFE. Citigroup reduced their target price on Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a report on Tuesday, January 28th. Truist Financial decreased their target price on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Finally, Bank of America reissued a "neutral" rating and issued a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $31.92.

Insider Activity

In other news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.06% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.